
-
TG Therapeutics NasdaqCM:TGTX TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Location: 3020 Carrington Mill Blvd., Morrisville, NC, 27560, United States | Website: https://www.tgtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.185B
Cash
276.2M
Avg Qtr Burn
-15.26M
Short % of Float
16.70%
Insider Ownership
9.70%
Institutional Own.
63.22%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BRIUMVI (ublituximab-xiiy) (CD20) Details Multiple sclerosis | Approved Quarterly sales | |
TG-1801 (anti-CD47/anti-CD19) Details B-cell malignancies, Cancer, B-cell lymphoma | Phase 1 Update | |
TG-1701 (BTK inhibitor) Details Chronic lymphocytic leukemia, Cancer | Phase 1 Update | |
BRIUMVI (ublituximab-xiiy) subcutaneous Details Multiple sclerosis | Phase 1 Update | |
UKONIQ® (Umbralisib) (PI3K-delta & CK1-epsilon inhibitor) Details FL (Follicular Lymphoma) | Failed Discontinued | |
Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia) | Failed Discontinued |